205 related articles for article (PubMed ID: 33070465)
41. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
42. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
43. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
[TBL] [Abstract][Full Text] [Related]
44. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
Pellicano F; Scott MT; Helgason GV; Hopcroft LE; Allan EK; Aspinall-O'Dea M; Copland M; Pierce A; Huntly BJ; Whetton AD; Holyoake TL
Stem Cells; 2014 Sep; 32(9):2324-37. PubMed ID: 24806995
[TBL] [Abstract][Full Text] [Related]
45. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
46. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia.
Brumatti G; Kaloni D; Castro FA; Amarante-Mendes GP
Biochem J; 2023 Jan; 480(2):161-176. PubMed ID: 36719792
[TBL] [Abstract][Full Text] [Related]
47. Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Bucur O; Stancu AL; Goganau I; Petrescu SM; Pennarun B; Bertomeu T; Dewar R; Khosravi-Far R
PLoS One; 2013; 8(10):e77390. PubMed ID: 24155950
[TBL] [Abstract][Full Text] [Related]
48. AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia.
Medeiros HCD; Colturato-Kido C; Ferraz LS; Costa CA; Moraes VWR; Paredes-Gamero EJ; Tersariol ILS; Rodrigues T
Chem Biol Interact; 2020 Jan; 315():108888. PubMed ID: 31682805
[TBL] [Abstract][Full Text] [Related]
49. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
50. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
[TBL] [Abstract][Full Text] [Related]
51. Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.
Hirano I; Nakamura S; Yokota D; Ono T; Shigeno K; Fujisawa S; Shinjo K; Ohnishi K
J Biol Chem; 2009 Aug; 284(33):22155-22165. PubMed ID: 19261608
[TBL] [Abstract][Full Text] [Related]
52. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
53. The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors.
Glowacki S; Synowiec E; Blasiak J
Int J Mol Sci; 2013 Aug; 14(8):16348-64. PubMed ID: 23965958
[TBL] [Abstract][Full Text] [Related]
54. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells.
Bandyopadhyay G; Biswas T; Roy KC; Mandal S; Mandal C; Pal BC; Bhattacharya S; Rakshit S; Bhattacharya DK; Chaudhuri U; Konar A; Bandyopadhyay S
Blood; 2004 Oct; 104(8):2514-22. PubMed ID: 15226183
[TBL] [Abstract][Full Text] [Related]
55. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
56. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
57. CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Burin SM; Ghisla S; Ouchida AT; Aissa AF; Coelho MG; Costa TR; Marsola AP; Pinto-Simões B; Antunes LM; Curti C; Sampaio SV; de Castro FA
Int J Biol Macromol; 2016 May; 86():309-20. PubMed ID: 26812110
[TBL] [Abstract][Full Text] [Related]
58. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
59. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
60. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
Puissant A; Robert G; Fenouille N; Luciano F; Cassuto JP; Raynaud S; Auberger P
Cancer Res; 2010 Feb; 70(3):1042-52. PubMed ID: 20103647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
